126
Participants
Start Date
October 31, 2003
Primary Completion Date
June 30, 2004
Study Completion Date
June 30, 2004
INGAP-Peptide
1.5 mL, once daily, self-administered SC injection for 90 days
INGAP-Peptide
1.5 mL, once daily, self-administered SC injection for 90 days
placebo
1.5 mL, once daily, self-administered SC injection for 90 days
Diabetes-Endocrinology Center of WNY, Buffalo
MedStar Clinical Research Center, Washington D.C.
Charlottesville Medical Research, Charlottesville
Piedmont Medical Group, Winston-Salem
UNC Diabetes Care Center, Durham
Mountain View Clinical Research, Greer
Mercury Street Medical, Butte
Dallas Diabetes and Endocrine Center, Dallas
University of Texas Health Science Center - Texas Diabetes Institute, San Antonio
DGD Research Associates, San Antonio
Denver
Longmont Medical Research Network, Longmont
Diabetes and Endocrine Associates, La Jolla
VA Hospital UCSD, San Diego
Diablo Clinical Research, Walnut Creek
Clinical Research Institute of Southern Oregon, Medford
Future Care Studies, Springfield
Lead Sponsor
Exsulin Corporation
INDUSTRY